G. Weil-Hillman

发表

Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo.

J. Sosman, J. Hank, P. Sondel, 1990, Cancer immunology, immunotherapy : CII.

In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

R. Bechhofer, B. Storer, J. Bradshaw, 1988, Cancer research.

The cellular immunotherapy of cancer: current and potential uses of interleukin-2.

J. Sosman, P. Fisch, J. Hank, 1989, Critical reviews in oncology/hematology.

Addition of interleukin-2in vitro augments detection of lymphokine-activated killer activity generatedin vivo

J. Sosman, J. Hank, P. Sondel, 2005, Cancer Immunology, Immunotherapy.

The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment.

J. Sosman, S. Voss, J. Hank, 1989, Bulletin of the New York Academy of Medicine.

Combined immunochemotherapy of human solid tumors in nude mice.

F. Uckun, D. Vallera, J. Manske, 1987, Cancer research.

Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.

D. Vallera, F. Jansen, G. Weil-Hillman, 1985, Cancer research.

leukemia class-I MHC antigens by IL-2-activated cytotoxic T cells from a patient with Antigen-specific recognition of autologous leukemia cells and allogeneic

Jacquelyn, J. Sosman, Michael, 2009 .

Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.

J. Sosman, P. Fisch, J. Hank, 1989, Cancer research.

Lymphokine-activated Killer Activity Induced by in Vivo Interleukin 2 Therapy : Predominant Role for Lymphocytes with Increased Expression of CD 2 and Leul 9 Antigens but Negative Expression of CD 16 Antigens 1

J. Sosman, P. Fisch, J. Hank, 2006 .

Antigen-specific recognition of autologous leukemia cells and allogeneic class-I MHC antigens by IL-2-activated cytotoxic T cells from a patient with acute T-cell leukemia.

J. Sosman, O. Colamonici, P. Fisch, 1989, Blood.

Natural Killer Cells Activated by Interleukin 2 Treatment in Vivo Respond to Interleukin 2 Primarily through the p75 Receptor and Maintain the p55 (TAC) Negative Phenotype1

Jacquelyn, J. Sosman, K. Sugamura, 2006 .

Natural Killer Cells Activated by Interleukin 2 Treatment in Vivo Respond to Interleukin 2 Primarily through the p 75 Receptor and Maintain the p 55 ( TAC ) Negative Phenotype 1

J. Sosman, K. Sugamura, P. Fisch, 2006 .

Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.

J. Sosman, K. Sugamura, P. Fisch, 1990, Cancer research.

Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL- 2 binding

K. Sugamura, M. Tsudo, S. Voss, 1990, The Journal of experimental medicine.

Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.

R. Bechhofer, J. Sosman, B. Storer, 1989, Cancer research.

Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients.

N. Rosenthal, J. Hank, P. Sondel, 1988, Journal of biological response modifiers.

Activation of Human T Cells Obtained Pre‐ and Post‐Interleukin‐2 (IL‐2) Therapy by Anti‐CD3 Monoclonal Antibody plus IL‐2: Implications for Combined In Vivo Treatment

J. Sosman, D. Segal, J. Hank, 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.